Prestige Consumer Healthcare Inc. (PBH): Entry into a Material Definitive Agreement
Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 tm2620415d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 INDENTURE Dated as of July 15, 2026 Among PRESTIGE BRANDS, INC., as the Issuer, the Guarantors from time to time party hereto and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee 6.250% SENIOR NOTES DUE 2034 TABLE OF
How this was made
The 30-second read
Why it matters
Debt indenture terms can influence perceived leverage, refinancing flexibility, and covenant headroom. Without proceeds and pricing details in the excerpt, the most actionable signal is for credit traders and relative value in PBH debt.
Market read
A new 6.250% senior notes due 2034 indenture (initial $400 million aggregate principal amount) is disclosed, which may affect PBH credit spreads and leverage expectations.
What to watch
Traders should look for missing details not shown here, such as issuance date, coupon yield vs. market, use of proceeds, and any changes to covenants or guarantees that could re-rate credit risk.
Background
The 8-K cites Item 1.01 (entry into a material definitive agreement) and Item 2.03 (creation of a direct financial obligation) and includes an indenture dated July 15, 2026 for 6.250% senior notes due 2034.
Ticker impact
Prestige Consumer Healthcare disclosed in an 8-K that it entered a material definitive agreement, including a 6.250% senior notes indenture due 2034.
Near-term price impact is likely limited unless the market interprets the debt terms as materially changing leverage or refinancing risk; watch credit spreads and PBH bond yields.
The text provides the indenture framework and principal amount ($400 million) but does not include proceeds use, pricing, or refinancing context beyond the agreement entry.
Market effects
Consumer staples/healthcare packaging and branded consumer health issuers may see read-across in credit conditions if the market treats the notes as a refinancing signal.
Primarily US credit markets via corporate bond issuance documentation.
Limited, as the disclosure is US SEC debt documentation with no cross-border transaction details in the provided text.
Counterpoint
If the notes are routine refinancing or already anticipated, equity impact may be negligible and the main effect would be confined to PBH credit/bond curves rather than the stock.
Key entities
- issuerPrestige Consumer Healthcare Inc.
Subject of the 8-K, filing for entry into a material definitive agreement and creation of a direct financial obligation via senior notes indenture.
- trusteeU.S. Bank Trust Company, National Association
Named trustee in the senior notes indenture agreement.
- issuer/guarantor entityPrestige Brands, Inc.
Named as the issuer in the indenture document among the parties.
